HUE028740T2 - Gyógyászati készítmény mometazon-furoáttal és azelasztin-hidrokloriddal nazális adagolásra - Google Patents
Gyógyászati készítmény mometazon-furoáttal és azelasztin-hidrokloriddal nazális adagolásra Download PDFInfo
- Publication number
- HUE028740T2 HUE028740T2 HUE11845222A HUE11845222A HUE028740T2 HU E028740 T2 HUE028740 T2 HU E028740T2 HU E11845222 A HUE11845222 A HU E11845222A HU E11845222 A HUE11845222 A HU E11845222A HU E028740 T2 HUE028740 T2 HU E028740T2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical composition
- nasal administration
- nasal
- volume
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (6)
1, Gyógyászati készítmény nazális adagol ásra* tóornetazon-ldojátí és azelasztin-hidrokíoriddai, Äl'i a gyógyászati lészftmény a kesérl ízt és Irritáeiot csókként# szerként tan-malmi tartalmaz.
2, Az I. igénypont sztóntl gyópaszaiíkészítmény nazális adagolásra, ától a fomoaün 0,1-0,5 sálydérlbgat % ntennpségben van Jelen.
3, Az I > Igénypont szerinti gyógyászati készítmény nazális adagolásra, ahol a gyógyászati készítmény 0,01-1 J söly/térfogat % raomstazon-tonatot; §,05-1,0 sóíy/téríbgaí % azeíasztín-líMreklöfídoí; 0.1-0,5 sólyAérfogái % tmnnatlni; 1,0-:5,0 sniy/forfogat % sirkőszert; #,2-0,6 sóly/térfogai % pnffer anyagot; 0,001-0,1 súiy/térfogat % felületaktív anyagét- 5,§-i0,O: sify/téríbgat % izetómás szert; 0,01-1,11 sűly/térlbgai % stabllzátort és 0,002-0,05 snly/térlbgat % tartósiószert tartalmaz vizes kózegtóm
4, A 3. igénypont szerinti gyógyászati készítmény nazális adagolásra, ahol a gyógyászati készítmény 0,01-1# sIlyAérfogat % mometazon-lhroátot; 0,05-1,0 snly/térlogat % azeíaszíín-hldrokferidoi; 0,Í-0J snly/iétfogai % taumatint; 1,0-5,0 siÍ$$Mefái: %· cellélóz és nátrióm-tórtel-ntetll-eelfulóz keveréket; 0,2-0,6 súly/térfogat 3¾ citrorasav és nátniím-eitíit keveréket; 0,001-0,1 snîÿ/tér fogai % poll(ozl-etlién:)-szorhltân-monôoleâîot; 5,0-10,0 sólyrtértogat "% glicerin és szerbi eíegyei; 0,01-1,0 sníyÉÉrfepi % nátrtum-edeíátoi és 0,0O2-0;05 sély/térfogat % benzalkóniora-kíntidot tartalmaz vizes közegben.
5, A 4, Igénypont szerinti gyógyászati készítmény nazális adagolásra, ahol a gyógyászati készítmény 0#S sniy/íériogat % mometazon-fhroáttól; 0,14 snly/térlbgat % azglasztln-hldrokloridtól; 0,25 sniy/tiribgat % taanratintól; 2,0 snly/térfept % mikrokristályos oellólóz és náfelnm-karboxómotii-eelfelóz elegyhol; 0# snly/térfogat % citromsavtói; 0,2S sóiy/térfegat % aátrinm^eitráiból; 0,0 í suly/térfopt % poltíoxl-etllin)~szorhittó-monoöfeátbók 2,1 súly/térfbgal % glicerinből; 6,ë súly/térfogat % szófiáiból; 0,1 sûiy/ïéribgsî % nátónm^edetátból.;: 0,02 súly/tárfbgaí % benzalkéní-um-kioridból : és & fmmmmâéê mennyiségig viaMl áll.
6. Az .1 .-5. igénypont bármelyike sæmnîi gyógyászati készítmény nazális adagolásra, ahol a gyógyászati készítményt nazális spray lomtára ármoláljak.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100119632A KR101261230B1 (ko) | 2010-11-29 | 2010-11-29 | 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028740T2 true HUE028740T2 (hu) | 2016-12-28 |
Family
ID=46172356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11845222A HUE028740T2 (hu) | 2010-11-29 | 2011-11-18 | Gyógyászati készítmény mometazon-furoáttal és azelasztin-hidrokloriddal nazális adagolásra |
Country Status (10)
Country | Link |
---|---|
US (1) | US8859531B2 (hu) |
EP (1) | EP2647380B1 (hu) |
JP (1) | JP5775597B2 (hu) |
KR (1) | KR101261230B1 (hu) |
CN (1) | CN103237550B (hu) |
BR (1) | BR112013012587A2 (hu) |
HU (1) | HUE028740T2 (hu) |
RU (1) | RU2563115C2 (hu) |
UA (1) | UA111343C2 (hu) |
WO (1) | WO2012074231A2 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
WO2015036902A1 (en) | 2013-09-13 | 2015-03-19 | Glenmark Pharmaceuticals Ltd | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
US9937189B2 (en) | 2013-09-13 | 2018-04-10 | Glenmark Specialty S.A. | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
CN103736098A (zh) * | 2013-12-27 | 2014-04-23 | 于运红 | 一种含有比拉斯汀及糠酸莫米松的鼻内给药用药物组合物 |
CA3002384C (en) * | 2015-10-25 | 2021-02-16 | Iview Therapeutics, Inc. | Pharmaceutical formulations that form gel in situ |
CN109288790A (zh) * | 2017-07-25 | 2019-02-01 | 健乔信元医药生技股份有限公司 | 鼻用医药组合物及其制备方法 |
JP6941889B2 (ja) | 2017-09-02 | 2021-09-29 | アイビュー セラピューティクス、インコーポレイテッド | インサイチュゲル形成医薬組成物および副鼻腔疾患のためのその使用 |
CN107737105A (zh) * | 2017-11-28 | 2018-02-27 | 贵州云峰药业有限公司 | 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺 |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
WO2022035388A1 (en) * | 2020-08-14 | 2022-02-17 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising azelastine and relevant excipients |
WO2022098319A1 (en) * | 2020-11-09 | 2022-05-12 | Pharmactive Ilac Sanayi Ve Ticarey A.S. | Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
WO2023014361A1 (en) * | 2021-08-05 | 2023-02-09 | La Pharma Tech Inc. | Novel pharmaceutical compositions and methods for treatment of psychiatric disorders |
WO2024079676A1 (en) * | 2022-10-12 | 2024-04-18 | Glenmark Specialty S.A. | Novel nasal spray assembling process |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE84968T1 (de) | 1987-11-13 | 1993-02-15 | Asta Medica Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
JP3190441B2 (ja) * | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | 塩酸アゼラスチンを含有する安定な製剤 |
AU6392496A (en) | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
EP1025858A4 (en) | 1998-08-28 | 2009-03-11 | Eisai R&D Man Co Ltd | DRUGS WITH REDUCED BITTERNESS ETC. |
DE10058459A1 (de) * | 2000-11-24 | 2002-06-06 | Haarmann & Reimer Gmbh | Rhinologica |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
NZ555501A (en) * | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
JP2009526064A (ja) * | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | 薬学的調合物 |
US20100099650A1 (en) * | 2006-10-10 | 2010-04-22 | Knauer Kent A | Nasal spray composition and method for treating rhinitis, sinusitis or both |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
JP2010138125A (ja) * | 2008-12-12 | 2010-06-24 | Kyukyu Yakuhin Kogyo Kk | 速溶性ニコチン含有フィルム製剤 |
-
2010
- 2010-11-29 KR KR1020100119632A patent/KR101261230B1/ko active IP Right Grant
-
2011
- 2011-11-18 CN CN201180057457.0A patent/CN103237550B/zh not_active Expired - Fee Related
- 2011-11-18 WO PCT/KR2011/008826 patent/WO2012074231A2/ko active Application Filing
- 2011-11-18 UA UAA201307541A patent/UA111343C2/uk unknown
- 2011-11-18 JP JP2013540886A patent/JP5775597B2/ja not_active Expired - Fee Related
- 2011-11-18 EP EP11845222.6A patent/EP2647380B1/en not_active Not-in-force
- 2011-11-18 BR BR112013012587A patent/BR112013012587A2/pt not_active Application Discontinuation
- 2011-11-18 RU RU2013124024/15A patent/RU2563115C2/ru not_active IP Right Cessation
- 2011-11-18 HU HUE11845222A patent/HUE028740T2/hu unknown
- 2011-11-18 US US13/990,373 patent/US8859531B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
UA111343C2 (uk) | 2016-04-25 |
JP2013543889A (ja) | 2013-12-09 |
CN103237550A (zh) | 2013-08-07 |
JP5775597B2 (ja) | 2015-09-09 |
CN103237550B (zh) | 2016-05-18 |
EP2647380A4 (en) | 2015-03-11 |
WO2012074231A3 (ko) | 2012-07-19 |
KR101261230B1 (ko) | 2013-05-07 |
KR20120058029A (ko) | 2012-06-07 |
WO2012074231A2 (ko) | 2012-06-07 |
RU2013124024A (ru) | 2015-01-10 |
EP2647380B1 (en) | 2016-02-03 |
RU2563115C2 (ru) | 2015-09-20 |
US8859531B2 (en) | 2014-10-14 |
EP2647380A2 (en) | 2013-10-09 |
BR112013012587A2 (pt) | 2016-09-06 |
US20130252929A1 (en) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE028740T2 (hu) | Gyógyászati készítmény mometazon-furoáttal és azelasztin-hidrokloriddal nazális adagolásra | |
AU2012204557B2 (en) | Bepotastine compositions | |
ES2756776T3 (es) | Formulación farmacéutica acuosa de tapentadol para administración oral | |
US11850222B2 (en) | Sotalol compositions and uses of the same | |
EA013351B1 (ru) | Фармацевтические препараты, содержащие бета-агонист длительного действия, для введения путем распыления | |
JP2006526004A (ja) | ロチゴチンの鼻腔内用処方 | |
EP3960158A1 (en) | Amlodipine formulations | |
WO2014092346A1 (en) | Bitter taste masked pharmaceutical formulation comprising corticosteroid, antihistamine and stevia | |
JP2013539758A (ja) | ベポタスチン組成物 | |
JP2015511213A (ja) | 薬物送達技術 | |
EP1543826B1 (en) | Concentrated aqueous solution of ambroxol | |
EP2934521B1 (en) | Use of pidotimod to treat psoriasis | |
KR20160145396A (ko) | 비강 분무용 약학 조성물 및 그 제조방법 | |
CN107737105A (zh) | 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺 | |
CN107929738A (zh) | 一种含盐酸氮卓斯汀的组合物 | |
WO2022025176A1 (ja) | 液剤組成物 | |
JP2022547755A (ja) | 白癬を防止又は処置するための医薬組成物 | |
BG111495A (bg) | Прахообразенфармацевтиченсъставсъдържащметамизол | |
KR20080113099A (ko) | 근육내 항바이러스 치료 |